Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Tiotropium, a novel once-daily inhaled anticholinergic, has been shown to improve lung function over a 24-h period. In order to extend these findings, health-outcomes were evaluated over 1 yr in chronic obstructive pulmonary disease (COPD) patients. Spirometric results, peak expiratory flow rate (PEFR), salbutamol use and effects on dyspnoea, health-related quality of life and COPD exacerbations were assessed in two identical 1-yr randomized double-blind double-dummy studies of tiotropium 18µg once daily (n=356) compared with ipratropium 40µg q.i.d.(n=179). Screening forced expiratory volume in one second (FEV 1) were 1.25±0.43 L (41.9±12.7% of the predicted value) (tiotropium) and 1.18±0.37 L (39.4±10.7% pred) (ipratropium). Trough FEV 1 at 1 yr improved by 0.12±0.01 L with tiotropium and declined by 0.03±0.02 L with ipratropium (p<0.001). Significant improvement in PEFR, salbutamol use, Transition Dyspnea Index focal score, and the St George's Respiratory Questionnaire total and impact scores were seen with tiotropium (p<0.01). Tiotropium reduced the number of exacerbations (by 24%, p<0.01), and increased time to first exacerbation (p<0.01) and time to first hospitalization for a COPD exacerbation (p<0.05) compared with ipratropium. Apart from an increased incidence of dry mouth in the tiotropium group, adverse events were similar between treatments. Tiotropium was effective in improving dyspnoea, exacerbations, health-related quality of life and lung function in patients with chronic obstructive pulmonary disease, and exceeds the benefits seen with ipratropium. The data support the use of tiotropium once-daily as first-line maintenance treatment in patients with chronic obstructive pulmonary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Lung volumes and forced ventilatory flows
Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J.-C. (1993) · European Respiratory Journal · doi:10.1183/09041950.005s1693 · Cited by 5,318
(1993) · PubMed · Cited by 3,827
Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease
Celli, B. R., Snider, G. L., Heffner, J. E., Tiep, B. L., Ziment, I., Make, B. J., Braman, S. S., Olsen, G. N., & D, Y. Y. P. M. (1995) · Cited by 3,506
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035
Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease
SEEMUNGAL, T. A. R., DONALDSON, G. C., PAUL, E. A., BESTALL, J. C., JEFFRIES, D. J., & WEDZICHA, J. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709032 · Cited by 2,312
Siafakas, N., Vermeire, P., Pride, N., Paoletti, P., Gibson, J., Howard, P., Yernault, J., Decramer, M., Higenbottam, T., Postma, D., et al. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08081398 · Cited by 1,592
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Seneff, M. G. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530230038027 · Cited by 593
Efficacy of Salmeterol Xinafoate in the Treatment of COPD
Mahler, D. A., Donohue, J. F., Barbee, R. A., Goldman, M. D., Gross, N. J., Wisniewski, M. E., Yancey, S. W., Zakes, B. A., Rickard, K. A., & Anderson, W. H. (1999) · Chest · doi:10.1378/chest.115.4.957 · Cited by 520
Quality of life changes in COPD patients treated with salmeterol.
Jones, P. W., & Bosh, T. K. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.4.9105068 · Cited by 494
O'DONNELL, D. E., LAM, M., & WEBB, K. A. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.9901038 · Cited by 485 · cited 1×
“Treatment with ipratropium leads to significant bronchodilation, with recent data suggesting other tangible benefits such as improvement in dyspnoea and hyperinflation and decreased exacerbations of COPD [13–17].”
BackgroundBelman, M. J., Botnick, W. C., & Shin, J. W. (1996) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.153.3.8630581 · Cited by 402 · cited 1×
“such as tiotropium is probably secondary to improvements in both airflow limitation and hyperinflation [19].”
BackgroundTiotropium (SPIRIVA™): Mechanistical considerations and clinical profile in obstructive lung disease
Disse, B., Speck, G. A., Rominger, K. L., Witek, T. J., & Hammer, R. (1999) · Life Sciences · doi:10.1016/s0024-3205(98)00588-8 · Cited by 274
RENNARD, S. I., ANDERSON, W., ZuWALLACK, R., BROUGHTON, J., BAILEY, W., FRIEDMAN, M., WISNIEWSKI, M., & RICKARD, K. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.9903053 · Cited by 265
Role of the Parasympathetic System in Airway Obstruction Due to Emphysema
Gross, N. J., & Skorodin, M. S. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408163110701 · Cited by 260
van Noord, J. A. (2000) · Thorax · doi:10.1136/thorax.55.4.289 · Cited by 249
Self-citationRespiratory Viral Infections in Adults With and Without Chronic Obstructive Pulmonary Disease
GREENBERG, S. B., ALLEN, M., WILSON, J., & ATMAR, R. L. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.1.9911019 · Cited by 246
LITTNER, M. R., ILOWITE, J. S., TASHKIN, D. P., FRIEDMAN, M., SERBY, C. W., MENJOGE, S. S., & WITEK, T. J. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.9903044 · Cited by 221
Molken, M. R.-V., Roos, B., & Van Noord, J. A. (1999) · Thorax · doi:10.1136/thx.54.11.995 · Cited by 194
Self-citationLong-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group.
Rand, C. S., Nides, M., Cowles, M. K., Wise, R. A., & Connett, J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.2.7633711 · Cited by 182
Friedman, M., Serby, C. W., Menjoge, S. S., Wilson, J. D., Hilleman, D. E., & Witek, T. J. (1999) · Chest · doi:10.1378/chest.115.3.635 · Cited by 175
Bronchodilator Responses to Anticholinergic and Beta-Adrenergic Agents in Acute and Stable COPD
Karpel, J. P. (1991) · CHEST Journal · doi:10.1378/chest.99.4.871 · Cited by 85
Role of the parasympathetic system in airway obstruction due to emphysema
Griffith, R. F. (1985) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(85)80112-8 · Cited by 47
Keistinen, T., Tuuponen, T., & Kivelä, S. (1998) · Respiratory Medicine · doi:10.1016/s0954-6111(98)90310-9 · Cited by 41
Cited by
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
Celli, B. R., MacNee, W., Agusti, A., Anzueto, A., Berg, B., Buist, A. S., Calverley, P. M. A., Chavannes, N., Dillard, T., Fahy, B., et al. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00014304 · Cited by 4,421
COPD exacerbations: Defining their cause and prevention
Wedzicha, J. A., & Seemungal, T. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61382-8 · Cited by 1,370
“[74] [75] [76] [77] Thus lowering the exacerbation rate would be expected to decrease hospitalisations and have important health economic benefi ts.”
Azithromycin for prevention of exacerbations of COPD
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104623 · Cited by 1,226
Metadata
- Authors
- Vincken, W., van Noord, J. A., Greefhorst, A. P. M., Bantje, T. A., Kesten, S., Korducki, L., & Cornelissen, P. J. G.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2002-02
- Volume
- 19
- Issue
- 2
- Pages
- 209-216
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2107045802
- Cited by
- 736
- References
- 27
- FWCI
- 60.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.